Connection

Stephen Tomlinson to Male

Back to Details
This is a "connection" page, showing publications Stephen Tomlinson has written about Male.
Stephen Tomlinson
Connection Strength
0.670
Male
  1. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
    View in: PubMed
    Score: 0.042
  2. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
    View in: PubMed
    Score: 0.041
  3. Complement mediates neuroinflammation and cognitive decline at extended chronic time points after traumatic brain injury. Acta Neuropathol Commun. 2021 04 20; 9(1):72.
    View in: PubMed
    Score: 0.040
  4. Complement Drives Synaptic Degeneration and Progressive Cognitive Decline in the Chronic Phase after Traumatic Brain Injury. J Neurosci. 2021 02 24; 41(8):1830-1843.
    View in: PubMed
    Score: 0.040
  5. Complement-Dependent Synaptic Uptake and Cognitive Decline after Stroke and Reperfusion Therapy. J Neurosci. 2020 05 13; 40(20):4042-4058.
    View in: PubMed
    Score: 0.038
  6. Acute Complement Inhibition Potentiates Neurorehabilitation and Enhances tPA-Mediated Neuroprotection. J Neurosci. 2018 07 18; 38(29):6527-6545.
    View in: PubMed
    Score: 0.033
  7. Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury. J Neurosci. 2018 03 07; 38(10):2519-2532.
    View in: PubMed
    Score: 0.032
  8. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
    View in: PubMed
    Score: 0.030
  9. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation. 2015 Dec 30; 12:247.
    View in: PubMed
    Score: 0.028
  10. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
    View in: PubMed
    Score: 0.026
  11. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
    View in: PubMed
    Score: 0.023
  12. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol. 2012 Nov 01; 189(9):4640-7.
    View in: PubMed
    Score: 0.022
  13. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
    View in: PubMed
    Score: 0.021
  14. Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol. 2010 Dec 01; 185(11):7007-13.
    View in: PubMed
    Score: 0.019
  15. Ketamine-xylazine-acepromazine compared with isoflurane for anesthesia during liver transplantation in rodents. J Am Assoc Lab Anim Sci. 2010 Jan; 49(1):45-51.
    View in: PubMed
    Score: 0.018
  16. Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res. 2009 Nov 20; 105(11):1094-101.
    View in: PubMed
    Score: 0.018
  17. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009 Oct 01; 183(7):4764-72.
    View in: PubMed
    Score: 0.018
  18. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 Jul; 50(7):3056-64.
    View in: PubMed
    Score: 0.017
  19. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
    View in: PubMed
    Score: 0.016
  20. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res. 2007 Oct 01; 67(19):9535-41.
    View in: PubMed
    Score: 0.016
  21. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006 Nov 15; 177(10):7266-74.
    View in: PubMed
    Score: 0.015
  22. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 2005 Nov 15; 65(22):10562-8.
    View in: PubMed
    Score: 0.014
  23. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
    View in: PubMed
    Score: 0.014
  24. The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology. 2004 Mar; 111(3):291-7.
    View in: PubMed
    Score: 0.012
  25. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
    View in: PubMed
    Score: 0.010
  26. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.
    View in: PubMed
    Score: 0.010
  27. Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight. 2018 12 20; 3(24).
    View in: PubMed
    Score: 0.009
  28. A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1728-37.
    View in: PubMed
    Score: 0.007
  29. Early Application of Auxiliary Partial Orthotopic Liver Transplantation in Murine Model of Wilson Disease. Transplantation. 2015 Nov; 99(11):2317-24.
    View in: PubMed
    Score: 0.007
  30. High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2015 May 20; 6(14):12654-67.
    View in: PubMed
    Score: 0.007
  31. Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem. 2015 Jan; 116(1):102-14.
    View in: PubMed
    Score: 0.007
  32. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis. 2014 May; 234(1):237-43.
    View in: PubMed
    Score: 0.006
  33. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol. 2009 Nov 01; 183(9):5928-37.
    View in: PubMed
    Score: 0.005
  34. Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol. 2008 Sep; 74(3):574-84.
    View in: PubMed
    Score: 0.004
  35. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
    View in: PubMed
    Score: 0.004
  36. A novel murine P-450 gene, Cyp4a14, is part of a cluster of Cyp4a and Cyp4b, but not of CYP4F, genes in mouse and humans. Biochem J. 1997 Aug 01; 325 ( Pt 3):741-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.